Table 3.
Homologies between thyroid peroxidase (TPO) and proteins from brain or central nervous system.
Protein [Entrez Protein GI accession number] | Protein segment | TPO segment | Identity | Overall homology* | E value | Coincidences with** | |||
---|---|---|---|---|---|---|---|---|---|
1 | Peroxidasin homolog/Melanoma-associated antigen MG50/Vascular peroxidase 1 [109150416] | 604–1314 | 8–734 | 41% | 58% | 1.89 × 10−175 | Eno | A | D |
2 | Peroxidasin-like protein [633365073] | 516–1201 | 40–734 | 38% | 55% | 5.01 × 10−150 | Eno | A | D |
3 | Prostaglandin G/H synthase 2/Cyclooxygenase-2 [4506265] | 208–340 | 318–459 | 28% | 43% | 1.50 × 10−8 | A | ||
4 | Prostaglandin G/H synthase 1/Cyclooxygenase-1 [18104967] | 227–518 | 324–650 | 22% | 40% | 1.35 × 10−5 | Eno | A | D |
5 | Fibrillin-1/Asprosin/Epididymis secretory sperm binding protein [311033452] | 515–572 | 768–840 | 32% | 47% | 0.011 | |||
570–613 | 794–840 | 36% | 55% | 0.129 | |||||
611–655 | 794–841 | 43% | 56% | 3.33 × 10−4 | |||||
723–765 | 796–840 | 37% | 55% | 0.015 | |||||
908–952 | 794–840 | 36% | 51% | 0.063 | |||||
1024–1070 | 792–840 | 38% | 48% | 0.005 | |||||
1068–1104 | 794–832 | 38% | 51% | 1.620 | |||||
1174–1238 | 774–840 | 29% | 46% | 1.196 | |||||
1216–1280 | 775–840 | 33% | 52% | 9.48 × 10−4 | |||||
1344–1404 | 776–840 | 38% | 55% | 4.31 × 10−5 | |||||
1392–1455 | 784–847 | 27% | 50% | 0.635 | |||||
1645–1692 | 793–843 | 35% | 45% | 0.166 | |||||
1888–1930 | 793–840 | 37% | 50% | 2.828 | |||||
1928–1973 | 794–840 | 53% | 63% | 8.86 × 10−7 | |||||
1973–2055 | 752–840 | 31% | 47% | 2.29 × 10−5 | |||||
2129–2199 | 740–832 | 30% | 45% | 0.005 | |||||
2244–2291 | 793–840 | 37% | 52% | 2.02 × 10−4 | |||||
2289–2334 | 794–841 | 33% | 47% | 0.546 | |||||
2413–2507 | 768–862 | 34% | 46% | 3.61 × 10−5 | |||||
2522–2567 | 794–840 | 36% | 46% | 0.340 | |||||
2575–2648 | 766–840 | 30% | 47% | 5.324 | |||||
2646–2678 | 794–829 | 47% | 58% | 0.198 | |||||
6 | Adhesion G protein-coupled receptor E2/EGF-like module receptor 2/CD312 [23397681] | 65–101 | 794–830 | 40% | 59% | 0.030 | |||
158–191 | 791–825 | 54% | 62% | 1.82 × 10−4 | |||||
209–240 | 793–825 | 45% | 63% | 0.155 | |||||
7 | Protocadherin Fat 4 [165932370] | 3799–3897 | 746–838 | 34% | 41% | 3.33 × 10−4 | |||
8 | Low-density lipoprotein receptor-related protein 4 (LRP-4) [157384998] | 359–433 | 747–838 | 33% | 46% | 4.08 × 10−4 | |||
9 | Latent-transforming growth factor beta-binding protein 4 (LTBP4) [110347431] | 355–397 | 794–839 | 36% | 54% | 0.431 | |||
585–636 | 794–847 | 38% | 50% | 0.506 | |||||
627–671 | 794–840 | 42% | 51% | 1.506 | |||||
750–794 | 794–840 | 44% | 59% | 0.064 | |||||
872–920 | 790–840 | 43% | 50% | 0.023 | |||||
1047–1091 | 794–840 | 51% | 61% | 5.63 × 10−4 | |||||
1539–1604 | 764–825 | 37% | 55% | 1.419 | |||||
10 | Fibrillin-3 [56237021] | 487–557 | 794–866 | 36% | 46% | 0.004 | |||
570–614 | 794–841 | 39% | 54% | 0.174 | |||||
681–724 | 795–840 | 39% | 56% | 0.323 | |||||
763–816 | 793–852 | 35% | 46% | 5.987 | |||||
867–911 | 794–840 | 44% | 53% | 0.396 | |||||
982–1028 | 792–840 | 42% | 44% | 0.874 | |||||
1153–1196 | 794–840 | 38% | 48% | 1.322 | |||||
1169–1238 | 770–840 | 35% | 47% | 0.074 | |||||
1443–1487 | 794–841 | 41% | 52% | 0.992 | |||||
1884–1930 | 794–841 | 43% | 52% | 0.041 | |||||
1959–2012 | 786–841 | 35% | 51% | 0.217 | |||||
2083–2148 | 795–862 | 35% | 45% | 0.196 | |||||
2204–2236 | 793–825 | 50% | 64% | 1.605 | |||||
2368–2468 | 762–862 | 31% | 42% | 0.001 | |||||
2483–2528 | 794–840 | 41% | 50% | 5.275 | |||||
2536–2601 | 766–831 | 39% | 52% | 0.078 | |||||
2598–2640 | 786–829 | 47% | 56% | 4.494 | |||||
11 | Latent-transforming growth factor beta-binding protein 1 (LTBP-1) [290457687] | 902–979 | 785–862 | 28% | 42% | 0.034 | |||
1074–1286 | 626–840 | 24% | 36% | 0.013 | Eno | ||||
1200–1244 | 794–840 | 43% | 56% | 0.001 | |||||
1436–1507 | 768–839 | 28% | 45% | 0.440 | |||||
1621–1706 | 738–839 | 29% | 36% | 2.230 | |||||
12 | Seizure related 6-like protein 2 [608785583] | 541–610 | 736–802 | 33% | 45% | 0.003 | |||
13 | CUB and sushi domain-containing protein 1 [259013213] | 1200–1282 | 739–805 | 29% | 38% | 0.968 | |||
2478–2555 | 727–797 | 34% | 48% | 0.003 | |||||
14 | C-type lectin domain family 14 member A/Epidermal growth factor receptor 5 (EGFR-5) [28269707] | 256–290 | 808–842 | 51% | 60% | 0.004 | |||
15 | fibrillin 1 variant, partial [62087260] | 438–490 | 786–840 | 38% | 54% | 0.005 | |||
16 | Multiple epidermal growth factor-like domains protein 6 [110347457] | 247–324 | 745–838 | 34% | 45% | 0.008 | |||
17 | Seizure 6-like protein/KIAA0927 protein [296179442] | 392–449 | 741–795 | 34% | 48% | 0.009 | |||
18 | Cadherin EGF LAG seven-pass G-type receptor 2/Cadherin family member 10/Flamingo homolog 3 [13325064] | 1296–1351 | 807–862 | 40% | 50% | 0.011 | |||
19 | Low-density lipoprotein receptor-related protein 2 (LRP-2) [126012573] | 1388–1428 | 794–838 | 40% | 51% | 0.386 | |||
3136–3191 | 767–838 | 31% | 44% | 0.550 | |||||
4000–4054 | 789–845 | 38% | 49% | 0.011 | |||||
20 | EGF-containing fibulin-like extracellular matrix protein 2 [14714634] | 121–164 | 794–840 | 44% | 48% | 0.272 | |||
141–203 | 772–840 | 34% | 50% | 0.012 | |||||
263–319 | 776–829 | 36% | 50% | 0.120 | |||||
21 | Nephronectin/Preosteoblast EGF-like repeat protein with MAM domain/EGFL6-like [75709198] | 212–259 | 794–847 | 38% | 61% | 0.016 | |||
22 | Complement component C1q receptor/CD93 [88758613] | 326–369 | 766–825 | 38% | 46% | 5.378 | |||
383–427 | 794–840 | 45% | 56% | 0.016 | |||||
410–468 | 767–839 | 34% | 45% | 0.367 | |||||
23 | Fibulin 5 [19743803] | 113–161 | 768–831 | 35% | 48% | 0.019 | |||
24 | Tolloid-like protein 1 [22547221] | 567–614 | 789–838 | 42% | 50% | 0.020 | |||
25 | EGF-containing fibulin-like extracellular matrix protein 1 [86788015] | 204–254 | 786–840 | 38% | 52% | 0.023 | |||
26 | Signal peptide, CUB and EGF-like domain-containing protein 1 [120587029] | 64–117 | 786–840 | 29% | 49% | 1.882 | |||
270–323 | 786–840 | 42% | 50% | 0.023 | |||||
360–407 | 794–844 | 33% | 56% | 3.772 | |||||
27 | Latent-transforming growth factor beta-binding protein 1 (LTBP1) [219518146] | 576–665 | 785–881 | 26% | 40% | 0.032 | |||
28 | KIAA1237 protein, partial [34327974] | 912–944 | 796–831 | 47% | 58% | 0.040 | |||
29 | Vitamin K-dependent protein S [192447438] | 137–201 | 776–840 | 32% | 50% | 0.041 | |||
30 | Protein HEG homolog 1 [153792110] | 1025–1057 | 796–831 | 47% | 58% | 0.047 | |||
31 | Low-density lipoprotein receptor-related protein 1B (LRP-1B) [93102379] | 96–155 | 793–840 | 28% | 41% | 5.824 | |||
104–193 | 745–838 | 28% | 45% | 0.049 | |||||
2909–2968 | 793–840 | 31% | 50% | 0.817 | |||||
2966–3002 | 794–834 | 46% | 63% | 0.081 | |||||
32 | P-selectin (CD62P)/Granule membrane protein 140/Leukocyte-endothelial cell adhesion molecule 3/Platelet activation dependent granule-external membrane protein [215274139] | 531–621 | 759–843 | 31% | 47% | 0.053 | |||
33 | Fibulin-1 (FIBL-1) [215274249] | 475–552 | 752–824 | 31% | 46% | 0.065 | |||
34 | Fibulin 1 [18490682] | 189–257 | 755–834 | 35% | 45% | 0.257 | |||
354–405 | 794–846 | 41% | 47% | 0.066 | |||||
390–441 | 787–840 | 37% | 51% | 0.404 | |||||
35 | Protein kinase C-binding protein NELL2 [223029476] | 461–500 | 794–834 | 43% | 58% | 0.067 | |||
36 | NOTCH4 protein [187954607] | 192–230 | 795–838 | 43% | 50% | 6.636 | |||
272–342 | 756–825 | 32% | 46% | 0.077 | |||||
37 | complement receptor type 2 [54792123] | 398–467 | 731–795 | 33% | 43% | 2.909 | |||
935–970 | 764–798 | 50% | 58% | 0.103 | |||||
38 | dual oxidase 2 precursor variant, partial [62087600] | 59–106 | 650–695 | 33% | 60% | 0.113 | |||
39 | Nidogen-1/Entactin [115298674] | 800–840 | 794–839 | 43% | 50% | 0.132 | |||
40 | CSMD2 protein [62954774] | 2404–2593 | 627–802 | 25% | 38% | 0.135 | Eno | ||
41 | Cysteine-rich with EGF-like Domains 2 (CRELD2) beta [67511376] | 202–266 | 767–839 | 35% | 45% | 0.135 | |||
42 | Endosialin/CD248 [9966885] | 283–356 | 755–844 | 26% | 38% | 0.203 | |||
43 | Epidermal growth factor-like protein 7 [7705889] | 137–185 | 796–847 | 40% | 50% | 0.208 | |||
44 | Prolow-density lipoprotein receptor-related protein 1/ Alpha-2-macroglobulin receptor/Apolipoprotein E receptor/CD91 [126012562] | 148–188 | 794–838 | 42% | 53% | 2.343 | |||
2941–3012 | 797–863 | 35% | 43% | 0.251 | |||||
45 | CUB and sushi domain-containing protein 3 [38045888] | 2874–2939 | 741–806 | 34% | 44% | 0.260 | |||
46 | Thrombospondin-3 [6005902] | 367–397 | 793–823 | 41% | 64% | 0.268 | |||
47 | Epidermal growth factor-like protein 6 [13124888] | 93–135 | 795–841 | 42% | 53% | 1.360 | |||
217–252 | 794–830 | 43% | 56% | 0.270 | |||||
48 | Mutant p53 binding protein 1 variant, partial [62087822] | 254–293 | 796–840 | 35% | 53% | 0.782 |
*Identical plus similar amino acids.
**Coincidences with segments of TPO homologous to known autoantigens of Hashimoto’s encephalopathy, i.e. alpha-enolase (Eno), AKRIAI (A) and DDAHI (D). Segments 603–627, 609–623, 637–659, 700–722, 710–721 of TPO are homologous to segments 261–281, 227–241, 211–233, 243–265, 346–357 of alpha-enolase, respectively. Segments 333–369, 410–456, 421–428 and 535–552 of TPO are homologous to segments 282–324, 22–72, 289–296 and 169–186 of AKRIAI, respectively. Segment 492–566 of TPO is homologous to segment 10–77 of DDAHI [25].